May 30, 2017
Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250

May 12, 2017
Patrick Amstutz Appointed as Chief Executive Officer

April 6, 2017
Molecular Partners discloses change in shareholder base

March 30, 2017
Symetis and Boston Scientific reach USD 435 million purchase agreement

March 20, 2017
MedTech Company Launches Large €55M IPO for Artificial Heart Valves

© Endeavour Vision SA 2006-2017 Terms & Conditions